Western Blot: ARNT/HIF-1 beta Antibody Pack [NB100-982] - Analysis of ARNT/HIF-1 beta using ARNT/HIF-1 beta antibody [NB100-110] from ARNT/HIF-1 beta antibody pack [NB100-982] in MCF7 whole cell lysate. Theoretical ...read more
Immunohistochemistry: ARNT/HIF-1 beta Antibody Pack [NB100-982] - Staining of skin, epidermis using ARNT/HIF-1 beta antibody [NB100-110] from the ARNT/HIF-1 beta antibody pack [NB100-982].
Chromatin Immunoprecipitation: ARNT/HIF-1 beta Antibody Pack [NB100-982] - Allele specific HIF-binding at the rs12814794 associated enhancer. B) Allele-specific qPCR for rs12814794 from DNA fragments isolated in ...read more
Western Blot: ARNT/HIF-1 beta Antibody Pack [NB100-982] - Expression of CD44 mRNA in genetically engineered MDA-MB-231 cells. (A) Immunoblot analysis of HIF-1a or HIF-2a expression in whole cell extracts from MDA-MB-231 ...read more
Western Blot: ARNT/HIF-1 beta Antibody Pack [NB100-982] - HIF was not the only factor stabilizing activated EGFR in VHL-deficient ccRCC cells. A. Western blot analysis of 786-VHL and 786-mock cells stably expressing ...read more
Immunohistochemistry: ARNT/HIF-1 beta Antibody Pack [NB100-982] - Staining of human glioblastoma multi-forme utilizing the ARNT/HIF-1 beta antibody[NB100-124] from the ARNT/HIF-1 beta antibody pack [NB100-982].
This pack contains1 vial each of: NB100-110 (0.1 mL) and NB100-124 (0.1 mL).
Alternate Names for ARNT/HIF-1 beta Antibody Pack
aryl hydrocarbon receptor nuclear translocator
Class E Basic Helix-Loop-Helix Protein 2
Dioxin Receptor, Nuclear Translocator
hypoxia-inducible factor 1, beta subunit
Hypoxia-inducible factor 1-beta
Aryl hydrocarbon nuclear translocator (ARNT), also commonly known as Hypoxia-inducible factor 1-beta (HIF-1 beta), is a ubiquitously expressed transcription factor that is part of the basic-helix-loop-helix (bHLH)-Per-ARNT-Sim (PAS) family (1, 2). Human arnt is located on chromosome 1q21 and encodes a protein 789 amino acids (aa) in length with a theoretical molecular weight of 87 kDa (1). Structurally, ARNT has a DNA binding bHLH domain, two PAS domains required for dimerization, and a transactivation domain/PAC region (1). ARNT belongs to the Class II bHLH-PAS proteins and is able to homodimerize or heterodimerize with the Class I proteins including AHA, AHRR, HIF-1 alpha, HIF-2 alpha, NPAS1, and SIM1 (2). Dimerization allows for efficient DNA binding and regulation of their target genes (2).
ARNT has an important role in two specific signaling pathways - the aryl hydrocarbon receptor (AhR) and the hypoxia inducible factor (HIF) pathway (1). In the AhR pathway, AhR in the cytosol is typically inactive and bound to heat shock protein 90 (hsp90) (3). Upon activation and ligand binding by environmental pollutants such as dioxins, AhR is translocated to the nucleus, dissociates from hsp90, and dimerizes with ARNT, leading to binding to response elements and expression of target genes including monooxygenases (1, 3). In the HIF pathway, under hypoxia (low oxygen) conditions prolylhydroxylase domain (PHD) enzymes and factor inhibiting HIF (FIH) are inhibited. HIF-1 alpha (or HIF-2 alpha) accumulates and is transported to the nucleus where it heterodimerizes with ARNT, allowing for binding to target gene's hypoxia response element (HRE), recruitment of coactivators, and transcription (1, 3). HIF-induced gene transcription plays a large role in tumor progression by promoting invasion, metastasis, de-differentiation and altered metabolism, and angiogenesis (1). While HIF-1 alpha's stability is dependent upon oxygen conditions, HIF-1 beta is stable in both normoxia and hypoxia (1-3).
The bHLH-PAS family and ARNT have been linked with a variety of pathologies and diseases including cancer, metabolic diseases, autoimmune diseases, and psychiatric disorders (2). ARNT/AHR is expressed in the skin and its pathway activation enhances skin barrier function and epidermal terminal differentiation, thus AHR agonists are currently being used as therapeutics for atopic dermatitis and psoriasis (4). Accordingly, studies of Arnt-deficient mice show profound abnormalities in skin barrier function and keratinization (4). Additionally, studies suggest that ARNT plays an important role in diabetes and beta-cell function (5). Islets from patients with type 2 diabetes have a significantly decreased ARNT expression compared to glucose-tolerant control donors (5). Modulation and stimulation of the HIF pathway may be a potential therapeutic strategy for treating type 2 diabetes and metabolic syndrome (5).
Alternate names for ARNT/HIF-1 beta include aryl hydrocarbon receptor nuclear translocator, BHLHE2, class E basic helix-loop-helix protein 2, Dixon receptor nuclear translocator, Hypoxia-inducible factor 1-beta, nuclear translocator, and TANGO.
1. Mandl, M., & Depping, R. (2014). Hypoxia-inducible aryl hydrocarbon receptor nuclear translocator (ARNT) (HIF-1beta): is it a rare exception?. Molecular medicine (Cambridge, Mass.). https://doi.org/10.2119/molmed.2014.00032
2. Wu, D., & Rastinejad, F. (2017). Structural characterization of mammalian bHLH-PAS transcription factors. Current opinion in structural biology. https://doi.org/10.1016/j.sbi.2016.09.011
3. Esser, C., & Rannug, A. (2015). The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacological reviews.https://doi.org/10.1124/pr.114.009001
4. Furue, M., Hashimoto-Hachiya, A., & Tsuji, G. (2019). Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis. International journal of molecular sciences. https://doi.org/10.3390/ijms20215424
5. Girgis, C. M., Cheng, K., Scott, C. H., & Gunton, J. E. (2012). Novel links between HIFs, type 2 diabetes, and metabolic syndrome. Trends in endocrinology and metabolism: TEM, https://doi.org/10.1016/j.tem.2012.05.003
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Antibody Packs are guaranteed for 1 year from date of receipt.
FAQs for ARNT/HIF-1 beta Antibody Pack (NB100-982). (Showing 1 - 4 of 4 FAQs).
Is this target appropriate for use in Chromatin Research?
Yes; here is a list of research areas that we have deemed appropriate for the target "ARNT/HIF-1 beta": Angiogenesis, Autophagy, Cancer, Cellular Markers, Chromatin Research, HIF Target Genes, Hypoxia, Transcription Factors and Regulators, Cardiovascular Biology, Lipid and Metabolism.
For use in Western Blot with HIF-1 beta antibodies, what molecular weight of the band should I expect to see?
The theoretical molecular weight determined by our technical team for ARNT/HIF-1 beta antibodies is 86.6 kDa.
If this product is used in an application or species as a part of a customer review, will that validate this product in the application/species?
If any of our primary antibodes are used in an untested application or species and it is shown to work through images from customer reviews or through publications, this validates the application/species for this product, allowing the tested application/species to fall under our 100% guarantee. Please check out our Innovator's Reward Program if you decide to test a primary antibody with a species or application that is not currently listed. Please note that the Innovator's Reward Program only applies to our primary antibodies.
Would you please help confirm the components of NB100-982? If NB100-982 really contains regular sizes of these 2 antibodies (not SS), the bargain seems too great to be true. However, if it is composed of NB100-110SS and NB100-124SS, the product seems too expensive.
NB100-982 contains 0.1ml of NB100-110 and 0.1ml of NB100-124.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.